CNSA-001 is an oral formulation of synthetic sepiapterin, an endogenous pterin

Sepiapterin is converted intracellularly into tetrahydrobiopterin, a cofactor for several important cell-based enzymes

Censa Pharmaceuticals is developing CNSA-001 as a therapy for diseases associated with deficiencies in tetrahydrobiopterin dependent enzymatic pathways

 

 

Developing Medicines to Improve the Lives of Patients with Debilitating Diseases

 

News